Jean Pierre Millon
CIK 1190016 · last filed 2024-11-25
Jean Pierre Millon is a corporate insider who has filed 62 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing shows the insider was granted $125.6K of CVS on Nov 25, 2024. Across all open-market trades the lifetime net is −$4.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $10.6M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CVS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CVS | Director | 112,217 | $94.48 | $10.60M | -$4.39M | 48 | 2024-11-25 |
| CYPRESS BIOSCIENCE INC (CYPB) Delisted | Director | — | — | — | $0 | 1 | 2010-01-06 |
| CYPRESS BIOSCIENCE INC (NSTR) Delisted | Director | — | — | — | $0 | 4 | 2009-01-07 |
| CAREMARK RX INC (CMX) Delisted | Director | 19,350 | — | — | $0 | 2 | 2007-02-16 |
Recent Filings
62 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-11-25 | CVS | Grant (A) | +2,200 | $125.6K | EDGAR |
| 2024-05-17 | CVS | Grant (A) | +2,314 | $133.1K | EDGAR |
| 2023-11-17 | CVS | Grant (A) | +1,925 | $133.1K | EDGAR |
| 2023-05-19 | CVS | Grant (A) | +1,437 | $99.6K | EDGAR |
| 2022-11-21 | CVS | Grant (A) | +1,402 | $133.1K | EDGAR |
| 2022-05-13 | CVS | Grant (A) | +1,409 | $138.1K | EDGAR |
| 2021-11-19 | CVS | Grant (A) | +1,253 | $116.2K | EDGAR |
| 2021-05-14 | CVS | Grant (A) | +1,379 | $116.2K | EDGAR |
| 2020-11-20 | CVS | Grant (A) | +1,752 | $116.2K | EDGAR |
| 2020-05-15 | CVS | Grant (A) | +1,865 | $116.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.